Clinical decision aid for nirsevimab (Beyfortus™) in newborn infants up to 6 months

 

Decision aid to determine if a newborn infant is eligible to receive nirsevimab.​ 

For an infant or child aged 7 months up to 24 months of age, refer to Clinical decision aid for nirsevimab (Beyfortus™) in infants and children​.

​​​​​​​​ Download  
​
Decision aid to determine if a newborn infant is eligible to receive nirsevimab. Text alternative follows image.  

Text alternative

  1. ​Is the infant 6 months of age?
    1. If no, the infant is not eligible for nirsevimab1
    2. If yes, did the mother receive the RSV vaccine (Abrysvo) during pregnancy?
      1. If no, recommend nirsevimab5 .
      2. If yes, was the maternal RSV vaccine (Abrysvo) received <2 weeks before birth?2
        1. ​If yes, provide nirsevimab5.
        2. If no, was infant born with risk conditions3 for severe RSV disease regardless of maternal vaccination status?
          1. If yes, provide nirsevimab 5.
          2. If no, was mother with severe immunosuppression4 where the immune resonse to maternally administered RSV vaccine was impaired?
            1. If yes, provide nirsevimab5.
            2. If no, has infont lost effective passive immunisation by having undergone a treatement after brith, such as exchange transfusion, cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) regardless of maternal vaccation status or if they ahve previously received a dose of nirsevimab?
              1. ​if yes, provide nirsevimab5.
              2. if no, nirsevimab not required.​

References

  1. Refer to the Clinical decision aid for nirsevimab (Beyfortus™) in infants and children up to 24 months of age who remain at risk of severe RSV disease.
  2. Check maternal RSV vaccination date on the Australian Immunisation Register
  3. Conditions associated with increased risk of severe RSV disease in infants and young children as
    recommended in the Australian Immunisation Handbook include:
    • preterm birth <32 weeks gestational age
    • Haemodynamically significant congenital heart disease 
    • significant immunosuppression, such as from solid organ transplant, haematopoietic stem cell transplant or primary immune deficiencies such as severe combined immunodeficiency (SCID) in consultation with a paediatric infectious disease, immunology or immunisation specialist.
    • chronic lung disease requiring ongoing oxygen or respiratory support
    • neurological conditions that impair respiratory function
    • cystic fibrosis with severe lung disease or weight for length <10th percentile
    • trisomy 21 or another genetic condition that increases the risk of
      severe RSV disease.
  4. Refer to the Australian Immunisation Handbook ​Vaccination for people who are immunocompromised chapter
  5. The dose of nirsevimab for infants weighing <5 kg, born during or entering their 1st RSV season, is 50 mg (0.5 mL). The dose of nirsevimab for infants weighing ≥5 kg, born during or entering their 1st RSV season, is 100 mg (1 mL). Nirsevimab is administered by intramuscular injection. Note: Newborn infants should receive nirsevimab prior to discharge from hospital. Primary care providers with an eligible infant up to 6 months of age who did not receive nirsevimab before discharge from hospital can order nirsevimab on the NSW State Vaccine Centre for eligible infants.
Current as at: Wednesday 26 November 2025
Contact page owner: Immunisation